Intelligent Bio Solutions (INBS) Gains from Investment Securities (2021 - 2023)
Intelligent Bio Solutions' quarterly Gains from Investment Securities came in at $1386.0 in Q2 2023, little changed quarter-over-quarter from $1386.0 in Q1 2023.
Intelligent Bio Solutions has reported Gains from Investment Securities for 3 years, with the latest figure at $1386.0 in Q2 2023.
- For the quarter ending Q2 2023, Gains from Investment Securities changed N/A year-over-year to $1386.0; the trailing twelve-month figure through Jun 2023 stood at $1386.0 (changed N/A YoY), and the FY2023 full-year result was $1386.0, changed N/A from the prior year.
- Gains from Investment Securities for Q2 2023 stood at $1386.0, roughly flat from $1386.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $27706.0 in Q4 2022, with the low at -$362667.0 in Q2 2021.
- Average Gains from Investment Securities over 3 years is -$83047.2, with a median of $1386.0 recorded in 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Intelligent Bio Solutions | 13.61 Mn | 12.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 1,386.00 |
| Jun 30, 2023 | 1,386.00 |
| Mar 31, 2023 | 1,386.00 |
| Mar 31, 2023 | 1,386.00 |
| Dec 31, 2022 | 27,706.00 |
| Dec 31, 2022 | 27,706.00 |
| Jun 30, 2021 | -362,667.00 |
| Jun 30, 2021 | -362,667.00 |